Improved risk stratification and detection of ILAs will provide a therapeutic window that could improve RA-ILD (interstitial lung disease) outcomes. CHEST Journal 2014;146(1):41-50. (Also see: Rheumatoid Arthritis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.